Tharimmune Expands Pipeline with HS1940 and HS3215 Biologics

Tharimmune Inc., a biotechnology company in Bridgewater, NJ, announced the expansion of its product pipeline with HS1940, a biparatopic biologic targeting PD-1 and VEGF receptors. Using its EpiClick Technology, HS1940 could enhance cancer treatment options by simultaneously engaging the PD-1 pathway and inhibiting angiogenesis.

The company has also introduced HS3215, a multispecific antibody targeting HER2 and HER3. This new approach offers potential advantages over current HER2-targeted therapies. Tharimmune aims to advance these biologics into clinical trials following successful preclinical testing.